: A 6-Month Extension Study Following Protocol VMDN-003-2 - An Adaptive, Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess Engensis in Participants With Painful Diabetic Peripheral Neuropathy
Latest Information Update: 21 Jan 2025
At a glance
- Drugs Donaperminogene seltoplasmid (Primary)
- Indications Diabetic neuropathies
- Focus Therapeutic Use
- Acronyms REGAiN-1B
- Sponsors Helixmith
Most Recent Events
- 16 Jan 2025 Status changed from recruiting to completed.
- 30 Jun 2022 Planned End Date changed from 1 Mar 2022 to 1 Dec 2023.
- 30 Jun 2022 Planned primary completion date changed from 1 Mar 2022 to 1 Oct 2023.